Cited 1 times in
Multicenter, phase II study of response-adapted lenalidomide-based therapy for transplant-ineligible patients with newly diagnosed multiple myeloma without high-risk features
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.